In this Issue:
CMX001 to prevent CMV disease post-SCT
Flow cytometric detection of dyserythropoiesis
Review and validation of EUTOS in imatinib-treated CML
Long-term outcomes with lenalidomide+dexamethasone for new MM
Optimal chemotherapy for younger AML patients
Single-agent lenalidomide in bortezomib-refractory/relapsed MCL
Imatinib discontinuation in CML patients with MR
Initial treatment and survival in advanced-stage HL
Lymphoma patients aged ≥90 years
Stomach cancer risk after HL treatment
Please login below to download this issue (PDF)